ISOPP CAPhO 2025 Symposium: Sponsored Lunch Symposium Johnson and Johnson - Latest Learnings and Best Practices for the Implementation of Bispecific Antibodies for Multiple Myeloma in the Community

This symposium will enable Canadian pharmacists involved in the management of relapsed/refractory Multiple Myeloma (RRMM) to determine the optimal patient selection and management strategies for triple class-exposed patients receiving bispecific antibodies, with a focus on administration in the Community setting.

Learning Objectives:

1. Explore patient selection for bispecific antibodies for the management of relapsed/refractory Multiple Myeloma (RRMM) in Canada
2. Share best practices for the optimal management of adverse events associated with bispecific antibodies for Multiple Myeloma
3. Consider the role of the pharmacist to support patient management and the delivery of bispecific antibodies for Multiple Myeloma within the Community setting